Patient is a 3 year old male who had neonatal hypoglycaemia and confirmed homozygosity for the GSD Type IIIa gene. Patient was commenced on the KD at 8 months of age when progression of his GSD resulted in severe cardiomyopathy. The following outlines the transition onto the KD and clinical findings between 8-22 months

Method Standard dietetic treatment was provided from birth to maintain euglycaemia along with placement of a percutaneous endoscopic gastrostomy. Continuous 24 hour feeding was required due to unsuccessful bolus feeding. A modified KD incorporating MCT fat -which was has been noted to further aid ketosis was commenced at 8 months with a ketogenic ratio of 0.5:1 building to 1:1 within 2 weeks. Ketones and blood sugar levels were closely monitored with a threshold of 2.6 mmol/L of glucose and ketones >1 mmol/L before hypoglycaemia intervention was required.

Results Prior to the KD, there was a high glucose infusion rate (GIR) of 9.75 mg glucose/kg/minute. After initiation of the KD, the GIR reduced initially to 5.8 mg glucose/kg/minute, with a gradual increase of MCT fat from 6% to 28% and the GIR further reduced to 2.73 mg glucose/kg/minute. There were no episodes of hypoglycaemia and ketones ranged from 1–2.9 mmol/L. Echocardiographs showed a significant improvement in cardiac function with a cardiac output reduction of 137 to 39 mmHg.

Discussion The KD was trialled as an alternative treatment. It resulted in the reduced intake of carbohydrate and the subsequent reduction of glycogen build-up within cardiac muscle. Ketones were used as an alternative fuel source and euglycaemia was maintained.

Conclusion The KD should be considered as an alternative treatment for GSD Type IIIa where standard intervention is not effective.

**GP230**
**FETAL ACETYLCHOLINE RECEPTOR INACTIVATION DUE TO MATERNAL MYASTHENIA GRAVIS: AN UNDERRECOGNISED, DEVASTATING BUT POTENTIALLY PREVENTABLE AND TREATABLE DISORDER**

1Mark O’Rahelly*, 2Andreas Hahn, 3Cam-Tu Nguyen, 4Dae-Seong Kim, 5Shin Y Byun, 6Ulfike Schara, 7Maria Henrich, 8Jan Morgan, 9Angela Vincent, 10Nicholas M Allen*, 11Heinz Jungbluth*.

1Department of Paediatrics, Galway University Hospital/National University of Ireland, Galway, Ireland; 2Department of Child Neurology, Feullgenst Giessen, Germany; 3Clinical Neurological Sciences, Children’s Hospital, London Health Sciences Centre, London, Ontario, Canada; 4Department of Paediatrics, Pusan National University School of Medicine, Busan, Korea, Republic of; 5Department of Paediatrics, Pusan National University School of Medicine, Busan, Korea, Republic of; 6Department of Paediatric Neurology, Developmental Neurology and Social Paediatrics, University of Essen, Essen, Germany; 7Department of Clinical Neurology, Oxford University, Oxford, UK; 8Department of Clinical Neurology, John Radcliffe Hospital, Oxford, UK; 9Department of Clinical Neurosciences, Weatherall, Institute of Molecular Medicine, University of Oxford, Oxford, UK; 10Department of Paediatric Neurology, Neuromuscular Service, Evelina’s Children Hospital, Guy’s and St Thomas’ Hospital NSF Foundation Trust, London, UK; 11Randall Division for Cell and Molecular Biophysics, Muscle Signalling Section, London, UK; 12Department of Basic and Clinical Neuroscience, IoPPN, King’s College, London, UK

Aim Fetal acetylcholine receptor inactivation syndrome (FARIS) occurs in offspring of mothers affected by myasthenia gravis (MG), from in-utero exposure to acetylcholine receptor (AChR)-antibodies targeting the fetal AChR γ-subunit. FARIS causes damage to the fetal neuromuscular junction which is crucial in muscle development, causing a persistent myopathy. FARIS may initially be mistaken for Transient Neonatal Myasthenia Gravis (TNMG), congenital neuromuscular disorders and one of the many causes of neonatal hypotonia. This study aimed to determine the clinical spectrum of FARIS and assess oral salbutamol as a novel pharmacological therapy.

Methods Detailed review of antenatal and postnatal clinical features in novel FARIS cases seen in international neuromuscular centres. Antibody data analysis was performed at the Oxford neuroimmunology research laboratory. Oral salbutamol was trialled in five cases based on previously reported benefit in one of our patients.

Results We identified 12 novel FARIS cases. At delivery resuscitation was required in all and intubation in nine, all had severe generalised hypotonia. Two infants with arrhythmophosis-multiplex-congenita phenotype died in the neonatal period. Among survivors, there was requirement for mechanical ventilation (n=9), NIPPV (n=2), oxygen (n=1), and supplemental NG/PEG feeding (n=12). The presence of severe generalised hypotonia with dysmorphic features prompted investigations for other neuromuscular, genetic and metabolic disorders which were negative. Common features included facial weakness (n=12) and limb contractures (n=9). Newly described disease features: diaphragmatic paresis (n=5), hearing impairment (n=3), CNS involvement (n=3), pyloric stenosis (n=2), extra-ocular eye restriction (n=2), non-progressive scoliosis (n=2), and jaw opening contracture (n=1). Motor development of patients improved with time. Respiratory complications (tracheostomy; n=2), feeding difficulties (PEG; n=2), facial weakness and speech impairment (from velopharyngeal incompetence) persisted in most. TNMG treatments (immunotherapy/pyridostigmine) were little or no benefit. Novel use of oral salbutamol improved fatiguability, ptosis, otorotor dysfunction, muscle tone, articulation and voice volume in all patients. In 8/12 pregnancies maternal myasthenia gravis hadn’t been established antenatally, and many mothers were pauci/asymptomatic. All had AChR-antibodies targeting the fetal γ-subunit confirming diagnosis. Where subsequent pregnancies were treated aggressively (immunotherapy), infants had improved outcomes.

Conclusions This report demonstrates and expands the phenotypic spectrum of FARIS, and emphasises oral salbutamol therapy as a potentially beneficial treatment. FARIS should be considered (mothers or infants tested for fetal specific AChR-Abs) in infants presenting with neonatal hypotonia, myopathic features and/or a suggestive antenatal history, even in the absence of a maternal MG diagnosis. Aggressive treatment with immunotherapy in pregnancy may improve outcomes.

**GP231**
**REVIEW OF INVESTIGATIONS CARRIED OUT DURING THE FIRST PRESENTATION OF ACQUIRED DEMYELINATING SYNDROMES OVER A TEN YEAR PERIOD**

Susan Harvey*, Niamh McSweeney. Cork University Hospital, Cork, Ireland

Aims A first episode of suspected demyelination presents a diagnostic challenge often having non-specific signs which overlap with other inflammatory white matter, neurometabolic and genetic disorders. The first episode may be a presentation of acute disseminated encephalomyelitis, multiple...
sclerosis, optic neuritis, transverse myelitis or NMO spectrum disorders. Associated morbidity and mortality of each is vastly different. Gaining accurate information through appropriate investigation is vital for appropriate treatment and counselling. There is currently no national or international guideline for investigation of an acute demyelinating event.

**Methods** Retrospective review of all cases of a first demyelinating event over a 10 year period (2008 – 2018) at Cork University Hospital. Laboratory investigations, imaging and clinic letters were reviewed.

**Results** In total eighteen cases were reviewed. Eventual diagnoses were 7 ADEM, 4 ADEM with transverse myelitis, 4 Multiple Sclerosis and 3 Optic Neuritis. Median presentation age was 6 years (1 year 4 months - 15 years 10 months). WCC and CSF microscopy was done in 100%. CRP and ESR done in 89% and 28% respectively. Investigations for bacterial and viral causes either on serum, CSF or swabs was inconsistent varying between 11–83%. CSF antibodies, including anti MOG, anti-NMDA, Aquaporin 4 and anti voltage gated potassium channel antibodies were sent in 6–39% of cases dependant on test. Oligodendral bands were sent in 83%. Imaging was undertaken in all cases with seventeen having an MRI Brain. Median time to MR brain was 1 day (0 days – 6 days). Fourteen cases had a MR spine with median time to spinal imaging of 2 days (1 day – 11 days).

**Conclusion** This review highlights the variable approach to investigation of suspected demyelination. The wide differential and need for prompt treatment to prevent long term neurological disability means there are multiple complex investigations required within a short time period. The laboratory investigations and neuroimaging required are labour intensive and incur significant financial cost. This is of particular importance in children, many of whom will require sedation and at times general anaesthetic to ensure successful obtaining of samples. The availability of a local protocol would guide clinicians investigation when faced with an unfamiliar presentation under significant time pressure. It would ensure appropriate and timely investigation enabling appropriate treatment and counselling.

**GP233**

**LIFESAVING MECHANICAL THROMBECTOMY IN PAEDIATRIC STROKE**

Emily Farnan*, 1MP O’Riordan Stephen, 2Noel Fanning, 2Gerald Wyse, 2Clodagh Ryan, 2Niamh Mc Sweeney.

1Department of Paediatrics and Child Health, Cork University Hospital, Cork, Ireland; 2Interventional Neuroradiology, Cork University Hospital, Cork, Ireland; 3Department of Paediatric Haematology, Mercy University Hospital, Cork, Ireland; 4Paediatric Neurology, Cork University Hospital, Cork, Ireland

Introduction Childhood arterial ischaemic stroke (AIS) is uncommon with a reported incidence between 1.2 and 7.91 per 100,000 per year.1,2,3 Previously it was thought that children with AIS had a good outcome due to brain plasticity; however, mortality has been reported in up to 28%, and morbidity in up to 70% of survivors.1,5 There are no randomised trials of mechanical thrombectomy in children. The 2017 published RCPCH stroke guidelines draw on the excellent outcomes for mechanical thrombectomy in adult trials and recommend referral for intra-arterial clot extraction in patients with NIHSS score of 6 or more and up to 12 hours post onset if there is salvageable brain tissue on imaging.6 There are only 29 paediatric cases published in the literature that have undergone mechanical thrombectomy, 12 of which were for posterior circulation AIS.